The Food and Drug Administration approved Shire Laboratories' drug ProAmatine (midodrine) in 1996 based on early results in treating low blood pressure. But the company has never conducted a mandatory follow-up study to actually prove the long-term benefits of the drug. The FDA has threatened to pull a drug off the market due to missing follow-up data.Saturday, September 4, 2010
Midodrine
The Food and Drug Administration approved Shire Laboratories' drug ProAmatine (midodrine) in 1996 based on early results in treating low blood pressure. But the company has never conducted a mandatory follow-up study to actually prove the long-term benefits of the drug. The FDA has threatened to pull a drug off the market due to missing follow-up data.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment